Get access

Neonatal clinical pharmacology

Authors

  • Karel Allegaert,

    Corresponding author
    1. Department of Development and Regeneration, KU Leuven, Leuven, Belgium
    2. Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium
    • Correspondence

      Karel Allegaert, Neonatal Intensive Care Unit, University Hospital, Herestraat 49, Leuven 3000, Belgium

      Email: karel.allegaert@uzleuven.be

    Search for more papers by this author
  • Marc van de Velde,

    1. Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
    2. Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium
    Search for more papers by this author
  • John van den Anker

    1. Division of Pediatric Clinical Pharmacology, Children's National Medical Center, Washington, USA
    2. Departments of Pediatrics, Pharmacology, Physiology and Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, WA, USA
    3. Intensive Care, Erasmus MC- Sophia Children's Hospital, Rotterdam, The Netherlands
    Search for more papers by this author

Summary

Effective and safe drug administration in neonates should be based on integrated knowledge on the evolving physiological characteristics of the infant who will receive the drug and the pharmacokinetics (PK) and pharmacodynamics (PD) of a given drug. Consequently, clinical pharmacology in neonates is as dynamic and diverse as the neonates we admit to our units while covariates explaining the variability are at least as relevant as median estimates. The unique setting of neonatal clinical pharmacology will be highlighted based on the hazards of simple extrapolation of maturational drug clearance when only based on ‘adult’ metabolism (propofol, paracetamol). Second, maturational trends are not at the same pace for all maturational processes. This will be illustrated based on the differences between hepatic and renal maturation (tramadol, morphine, midazolam). Finally, pharmacogenetics should be tailored to neonates, not just mirror adult concepts. Because of this diversity, clinical research in the field of neonatal clinical pharmacology is urgently needed and facilitated through PK/PD modeling. In addition, irrespective of already available data to guide pharmacotherapy, pharmacovigilance is needed to recognize specific side effects. Consequently, pediatric anesthesiologists should consider to contribute to improved pharmacotherapy through clinical trial design and collaboration, as well as reporting on adverse effects of specific drugs.

Ancillary